Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
104.00
+3.00 (2.97%)
May 8, 2026, 1:30 PM CST
Market Cap161.86B +34.7%
Revenue (ttm)38.04M -6.0%
Net Income-284.11M
EPS-0.18
Shares Out1.56B
PE Ration/a
Forward PE33.41
Dividendn/a
Ex-Dividend Daten/a
Volume5,258,861
Average Volume7,754,391
Open103.00
Previous Close101.00
Day's Range101.50 - 105.00
52-Week Range69.90 - 277.00
Beta1.28
RSI47.79
Earnings DateAug 10, 2026

About TPE:6919

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Tai... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2025, TPE:6919's revenue was 38.04 million, a decrease of -14.40% compared to the previous year's 44.43 million. Losses were -351.92 million, -40.23% less than in 2024.

Financial Statements